Efficacy and possible mechanisms of action of Selank in generalized anxiety disorders and neurasthenia
A A Zozulia, G G Neznamov, T S Siuniakov, N V Kost, M V Gabaeva, O Iu Sokolov, E V Serebriakova, O A Siranchieva, A V Andriushenko, E S Telesheva, S A Siuniakov, A B Smulevich, N F Miasoedov, S B Seredenin · 2008 · Zh Nevrol Psikhiatr Im S S Korsakova. 108(4):38–48
What does this source report?
The authors report similar anxiety changes with the two treatments and assess serum enkephalin metabolism.
- Population and setting
- 62 patients; treatment-arm counts conflict between indexed abstract (30/32) and abridged reprint (42/20)
- Evidence type
- Randomized trial
- Preparation
- Original Semax / Selank research preparations; no equivalence to modified commercial analogues asserted
- Source language
- See original publication; indexed English metadata
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Original journal version needed to resolve treatment-arm discrepancy. Diagnostic groups (30 anxiety, 32 neurasthenia) must not be substituted for treatment groups.
- Allocation concealment and blinding remain unresolved.
- Active-comparator similarity does not establish noninferiority or long-term safety.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Indexed abstract plus abridged commercial-hosted reprint
Review depth: Abstract and selected reprint methods; source discrepancy
Source access and review scope
Indexed abstract and branded-site abridged PDF methods checked. The PDF explicitly states it is shortened; it is not the complete original article.
Recorded source-check date: 2026-10-02. This date does not imply a completed systematic review.
Source provenance: Journal publication
Cite and trace this record
Original source: A A Zozulia, G G Neznamov, T S Siuniakov, N V Kost, M V Gabaeva, O Iu Sokolov, E V Serebriakova, O A Siranchieva, A V Andriushenko, E S Telesheva, S A Siuniakov, A B Smulevich, N F Miasoedov, S B Seredenin. Efficacy and possible mechanisms of action of Selank in generalized anxiety disorders and neurasthenia Zh Nevrol Psikhiatr Im S S Korsakova. 108(4):38–48 2008.
Molekul research summary: https://molekul.io/research/ss-18454096. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry